William Meyers
Contributor since: 2011
Latest Articles
Celldex Therapeutics Salvage Value
GlaxoSmithKline Combines Dividend With Growth Potential
Immunomedics: Short-Term Risk, Long-Term Opportunity
Acceleron: Luspatercept New Data Is A Buy Signal
5 Reasons Why Celgene Will Recover
Athenex: Wait To See New Drug Pricing
Achaogen: Buy Before The June 25 PDUFA Date
Tetraphase Pharmaceuticals, My Favorite 2H 2018 Biotech
Regeneron Unknown: Eylea Future Competition Effects
Seattle Genetics Fairly Valued, Pending Data
Biogen Buy Signal: Alzheimer's Royalties Option
Xilinx's ACAP Could Be A Computing Game-Changer
Biogen's Ionis Deal Is Brilliant
Merrimack Pharmaceuticals Potential Catalyst A Likely Bust
Akcea Undervalued As Commercial Launches Near
GlycoMimetics: Buy This Dip
Tocagen Drug Candidate Looks Undervalued, But Very Risky
Agenus: Mystery Therapy Indicates Possible Upside
Biogen's Key Variable: Its Neuroscience Pipeline
Ionis Is A Buy On RNA Platform Pipeline
Tetraphase Pharmaceuticals Trial Failure May Mask Value
Amgen: Outlook
Syndax Pharmaceuticals Undervalued On Coming Data Readouts
Reata Pharmaceuticals A Buy On Bardoxolene Data
Celldex Value Depends On Coming Data
ImmunoGen Price Run-Up Driven By Potential Clinical Trial Data
Endocyte, Now Included In IBB, Has A Strong Clinical-Stage Asset
Why GlycoMimetics Is Up Over 400% In Less Than A Year
Agios Gears Up Pipeline To Create Future Value
BiTE Amgen For Long-Term Returns
Gilead Sciences: Going Down When It Should Go Up
Celgene Is Oversold, Buy And Keep Until At Least 2020